{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:08:55Z","timestamp":1778562535897,"version":"3.51.4"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008903","name":"Republic of China Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW110-TDU-B-212-144020"],"award-info":[{"award-number":["MOHW110-TDU-B-212-144020"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010613","name":"Taipei Medical University Hospital","doi-asserted-by":"publisher","award":["106TMU-TMUH-10"],"award-info":[{"award-number":["106TMU-TMUH-10"]}],"id":[{"id":"10.13039\/501100010613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2320-B-038-040-MY3"],"award-info":[{"award-number":["MOST 110-2320-B-038-040-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["108-2320-B-038-058-MY3"],"award-info":[{"award-number":["108-2320-B-038-058-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","award":["AS-BRPT-110-06"],"award-info":[{"award-number":["AS-BRPT-110-06"]}],"id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.phymed.2022.154061","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T03:11:28Z","timestamp":1647400288000},"page":"154061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia"],"prefix":"10.1016","volume":"100","author":[{"given":"Shih-Chung","family":"Yen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Chiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Wu","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6866-7034","authenticated-orcid":false,"given":"Huang-Ju","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-3848","authenticated-orcid":false,"given":"Liang-Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-0224","authenticated-orcid":false,"given":"Tony Eight","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Ying","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ju","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Chun","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Jan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Ron","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chun","family":"HuangFu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiow-Lin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-6673","authenticated-orcid":false,"given":"Kai-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phymed.2022.154061_bib0001","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/cancers11010028","article-title":"Flavonoids in cancer and apoptosis","volume":"11","author":"Abotaleb","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.phymed.2022.154061_bib0002","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1016\/j.celrep.2018.11.063","article-title":"CDK phosphorylation of translation initiation factors couples protein translation with cell-cycle transition","volume":"25","author":"An","year":"2018","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.phymed.2022.154061_bib0003","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.phymed.2022.154061_bib0004","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.phymed.2022.154061_bib0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s13205-013-0117-5","article-title":"Anti-cancer potential of flavonoids: recent trends and future perspectives","volume":"3","author":"Batra","year":"2013","journal-title":"3 Biotech"},{"issue":"2","key":"10.1016\/j.phymed.2022.154061_bib0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ijc.2910580207","article-title":"Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer","volume":"58","author":"Berrozpe","year":"1994","journal-title":"Int. J. Cancer"},{"issue":"17","key":"10.1016\/j.phymed.2022.154061_bib0007","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2007-11-126664","article-title":"A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML","volume":"113","author":"Breitenbuecher","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.phymed.2022.154061_bib0008","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J. Clin. Oncol."},{"issue":"D1","key":"10.1016\/j.phymed.2022.154061_bib0009","doi-asserted-by":"crossref","first-page":"D437","DOI":"10.1093\/nar\/gkaa1038","article-title":"RCSB protein data bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences","volume":"49","author":"Burley","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.phymed.2022.154061_bib0010","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.phymed.2022.154061_bib0011","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-015-0176-7","article-title":"The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo","volume":"8","author":"Chao","year":"2015","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.phymed.2022.154061_bib0012","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1021\/acs.jnatprod.5b00324","article-title":"Total synthesis of hispidulin and the structural basis for its inhibition of proto-oncogene kinase Pim-1","volume":"78","author":"Chao","year":"2015","journal-title":"J. Nat. Prod."},{"issue":"11","key":"10.1016\/j.phymed.2022.154061_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22111897","article-title":"Total synthesis and metabolic stability of hispidulin and its D-labelled derivative","volume":"22","author":"Chen","year":"2017","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.phymed.2022.154061_bib0014","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1021\/acs.jnatprod.0c00516","article-title":"Biological evaluation of selected flavonoids as inhibitors of MNKs targeting acute myeloid leukemia","volume":"83","author":"Chen","year":"2020","journal-title":"J. Nat. Prod."},{"issue":"4","key":"10.1016\/j.phymed.2022.154061_bib0015","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6892","key":"10.1016\/j.phymed.2022.154061_bib0016","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phymed.2022.154061_bib0017","doi-asserted-by":"crossref","DOI":"10.4322\/acr.2018.084","article-title":"JAK2-mutated acute myeloid leukemia: comparison of next-generation sequencing (NGS) and single nucleotide polymorphism array (SNPa) findings between two cases","volume":"9","author":"de Noronha","year":"2019","journal-title":"Autops. Case Rep."},{"issue":"1","key":"10.1016\/j.phymed.2022.154061_bib0018","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.075","article-title":"Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy","volume":"6","author":"Del Principe","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.phymed.2022.154061_bib0019","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ejmech.2017.08.006","article-title":"Dual inhibition of MNK2 and FLT3 for potential treatment of acute myeloid leukaemia","volume":"139","author":"Diab","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.phymed.2022.154061_bib0020","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.phymed.2022.154061_bib0021","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","article-title":"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia","volume":"119","author":"Eghtedar","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.phymed.2022.154061_bib0022","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/ejh.12841","article-title":"The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia","volume":"98","author":"Fathi","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"14","key":"10.1016\/j.phymed.2022.154061_bib0023","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.3390\/ijms20143429","article-title":"Targeting tyrosine kinases in acute myeloid leukemia: why, who and how?","volume":"20","author":"Fernandez","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.phymed.2022.154061_bib0024","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.phymed.2022.154061_bib0037","unstructured":"LeadIT version 2.3.2; BioSolveIT GmbH, Sankt Augustin, Germany, 2017, www.biosolveit.de\/LeadIT."},{"issue":"1","key":"10.1016\/j.phymed.2022.154061_bib0025","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol. Rev."},{"issue":"11","key":"10.1016\/j.phymed.2022.154061_bib0026","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/14786410902847302","article-title":"Isolation and synthesis of flavonols and comparison of their antioxidant activity","volume":"24","author":"Hasan","year":"2010","journal-title":"Nat. Prod. Res."},{"issue":"6","key":"10.1016\/j.phymed.2022.154061_bib0027","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","article-title":"The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors","volume":"16","author":"Hedvat","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.phymed.2022.154061_bib0028","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/leu.2017.284","article-title":"RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia","volume":"32","author":"Hospital","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.phymed.2022.154061_bib0029","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","article-title":"Mutation analysis of 24 known cancer genes in the NCI-60 cell line set","volume":"5","author":"Ikediobi","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"D1","key":"10.1016\/j.phymed.2022.154061_bib0030","doi-asserted-by":"crossref","first-page":"D562","DOI":"10.1093\/nar\/gkaa895","article-title":"KLIFS: an overhaul after the first 5 years of supporting kinase research","volume":"49","author":"Kanev","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.phymed.2022.154061_bib0031","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/10428194.2013.800198","article-title":"FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations","volume":"55","author":"Kayser","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phymed.2022.154061_bib0032","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10","key":"10.1016\/j.phymed.2022.154061_bib0033","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1182\/blood-2003-06-2071","article-title":"Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia","volume":"103","author":"Kindler","year":"2004","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.phymed.2022.154061_bib0034","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","article-title":"FLT3 as a therapeutic target in AML: still challenging after all these years","volume":"116","author":"Kindler","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.phymed.2022.154061_bib0035","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2006-04-015487","article-title":"The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.phymed.2022.154061_bib0036","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cyto.2016.01.024","article-title":"Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia","volume":"89","author":"Kosciuczuk","year":"2017","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.phymed.2022.154061_bib0038","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/1940-6207.CAPR-12-0425","article-title":"Direct targeting of MEK1\/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth","volume":"6","author":"Lee","year":"2013","journal-title":"Cancer Prev. Res."},{"issue":"1","key":"10.1016\/j.phymed.2022.154061_bib0039","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12906-018-2310-x","article-title":"Comparison of the main components and bioactivity of Rhus verniciflua Stokes extracts by different detoxification processing methods","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Complement. Altern. Med."},{"issue":"5","key":"10.1016\/j.phymed.2022.154061_bib0040","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/leu.2017.43","article-title":"Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition","volume":"31","author":"Leroy","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.phymed.2022.154061_bib0041","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/blood-2011-06-363960","article-title":"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation","volume":"119","author":"Man","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.phymed.2022.154061_bib0042","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-13-0279","article-title":"Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors","volume":"20","author":"Meyer","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"35","key":"10.1016\/j.phymed.2022.154061_bib0043","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.phymed.2022.154061_bib0044","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/15384101.2015.1007751","article-title":"Engagement of DYRK2 in proper control for cell division","volume":"14","author":"Nihira","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.phymed.2022.154061_bib0045","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1017\/jns.2016.41","article-title":"Flavonoids: an overview","volume":"5","author":"Panche","year":"2016","journal-title":"J. Nutr. Sci."},{"issue":"10","key":"10.1016\/j.phymed.2022.154061_bib0046","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s12276-020-00515-5","article-title":"DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.phymed.2022.154061_bib0047","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3324\/haematol.2009.013797","article-title":"Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia","volume":"95","author":"Park","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.phymed.2022.154061_bib0048","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/10408398.2012.656770","article-title":"Flavonoids and immune function in human: a systematic review","volume":"55","author":"Peluso","year":"2015","journal-title":"Crit. Rev. Food Sci. Nutr."},{"issue":"12","key":"10.1016\/j.phymed.2022.154061_bib0049","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3324\/haematol.11345","article-title":"Imatinib mesylate in the treatment of newly diagnosed or refractory\/resistant c-KIT positive acute myeloid leukemia. Results of an Italian multicentric phase II study","volume":"92","author":"Piccaluga","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.phymed.2022.154061_bib0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MOH.0000000000000022","article-title":"Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?","volume":"21","author":"Pratz","year":"2014","journal-title":"Curr. Opin. Hematol."},{"issue":"12","key":"10.1016\/j.phymed.2022.154061_bib0051","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1016\/j.biocel.2013.10.004","article-title":"Flavonoids as prospective compounds for anti-cancer therapy","volume":"45","author":"Ravishankar","year":"2013","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"19\u201320","key":"10.1016\/j.phymed.2022.154061_bib0052","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00018-004-4189-6","article-title":"Signal transduction via the stem cell factor receptor\/c-Kit","volume":"61","author":"Ronnstrand","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"issue":"12","key":"10.1016\/j.phymed.2022.154061_bib0053","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/ph13120418","article-title":"CDK4\/6 and MAPK-crosstalk as opportunity for cancer treatment","volume":"13","author":"Scheiblecker","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.phymed.2022.154061_bib0054","doi-asserted-by":"crossref","first-page":"313","DOI":"10.14694\/EdBook_AM.2013.33.313","article-title":"The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia","author":"Smith","year":"2013","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"2","key":"10.1016\/j.phymed.2022.154061_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1034\/j.1600-0609.2001.t01-1-00385.x","article-title":"Constitutive activation of STAT transcription factors in acute myelogenous leukemia","volume":"67","author":"Spiekermann","year":"2001","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.phymed.2022.154061_bib0056","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/leu.2011.66","article-title":"Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy","volume":"25","author":"Steelman","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.phymed.2022.154061_bib0057","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2004.04808.x","article-title":"Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia","volume":"124","author":"Stirewalt","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.phymed.2022.154061_bib0058","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.phymed.2022.154061_bib0059","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1124\/mol.115.098012","article-title":"Pharmacologic inhibition of MNKs in acute myeloid leukemia","volume":"88","author":"Teo","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.phymed.2022.154061_bib0060","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1021\/cb300729y","article-title":"De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments","volume":"8","author":"Urich","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"21","key":"10.1016\/j.phymed.2022.154061_bib0061","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.phymed.2022.154061_bib0062","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2007-02-071266","article-title":"Pharmacologic inhibition of CDK4\/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia","volume":"110","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.phymed.2022.154061_bib0063","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12870-014-0347-7","article-title":"Functional analysis of flavonoid 3\u2032,5\u2032-hydroxylase from tea plant (Camellia sinensis): critical role in the accumulation of catechins","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Plant Biol."},{"issue":"15","key":"10.1016\/j.phymed.2022.154061_bib0064","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1158\/0008-5472.CAN-06-0419","article-title":"Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo","volume":"66","author":"Wendel","year":"2006","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.phymed.2022.154061_bib0065","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1101\/gad.1604407","article-title":"Dissecting eIF4E action in tumorigenesis","volume":"21","author":"Wendel","year":"2007","journal-title":"Genes Dev."},{"issue":"8","key":"10.1016\/j.phymed.2022.154061_bib0066","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.phymed.2022.154061_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acs.jnatprod.0c00589","article-title":"Investigation of selected flavonoid derivatives as potent FLT3 inhibitors for the potential treatment of acute myeloid leukemia","volume":"84","author":"Yen","year":"2021","journal-title":"J. Nat. Prod."},{"issue":"11","key":"10.1016\/j.phymed.2022.154061_bib0068","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1111\/cas.13792","article-title":"Tumor suppressive role for kinases phosphorylating p53 in DNA damage-induced apoptosis","volume":"109","author":"Yogosawa","year":"2018","journal-title":"Cancer Sci."},{"issue":"21","key":"10.1016\/j.phymed.2022.154061_bib0069","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/1873-3468.13601","article-title":"Multiple functions of DYRK2 in cancer and tissue development","volume":"593","author":"Yoshida","year":"2019","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.phymed.2022.154061_bib0070","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3892\/ijmm.2020.4592","article-title":"The JAK2\/STAT3 pathway inhibitor, AG490, suppresses the abnormal behavior of keloid fibroblasts in vitro","volume":"46","author":"Zhou","year":"2020","journal-title":"Int. J. Mol. Med."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711322001398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711322001398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:15:05Z","timestamp":1778559305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711322001398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":70,"alternative-id":["S0944711322001398"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2022.154061","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2022.154061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"154061"}}